Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Minéral 89 Probiotic Fractions
- Development stage
- Preclinical
- Lead developer
- Vichy
- Modality
- Small Molecules, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Peptides, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Topical
01
Overview
Minéral 89 Probiotic Fractions is a dermo-cosmetic formulation developed by Vichy Laboratoires (a L'Oréal brand) specifically designed to repair and reinforce the skin's barrier function. It is formulated with probiotic fractions derived from the bacterium *Vitreoscilla filiformis* cultured in Vichy volcanic water, combined with 4% niacinamide and hyaluronic acid. The product aims to address signs of stressed skin, including dullness, fine lines, and loss of elasticity, as well as clinical conditions such as rosacea and extreme skin sensitivity. Its mechanism involves modulating the skin's natural defenses and immune response while providing intense hydration and reducing inflammation and transepidermal water loss (TEWL).
- Brand names
- Vichy Minéral 89 Probiotic Fractions
- Other names
- M89 probiotic fractionsM-89 probiotic fractionsM 89 probiotic fractionsMinéral 89 Probiotic Fractions Serum
02
Targets
CD44 (CD44 antigen)TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on Minéral 89 Probiotic Fractions.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Minéral 89 Probiotic Fractions.